We are a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (“ADCs”) for patients suffering from hematological malignancies and solid tumors.
$23.00 - $26.00
October 3, 2019
MORGAN STANLEY & CO. LLC,MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED
This offering is no longer available
Sign Up to participate in future offerings
To view the prospectus for ADC Therapeutics IPO, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277